US6291228B1
(en)
|
1988-08-03 |
2001-09-18 |
Vericore Limited |
Vaccine
|
GB8919819D0
(en)
*
|
1989-09-01 |
1989-10-18 |
Coopers Animal Health |
Complexes having adjuvant activity
|
NL9002314A
(nl)
*
|
1990-10-23 |
1992-05-18 |
Nederlanden Staat |
Immunogene complexen, in het bijzonder iscoms.
|
SE502569C2
(sv)
*
|
1991-05-31 |
1995-11-13 |
British Tech Group |
Användning av en immunologiskt inert matris av en sterol och saponiner som kan bilda sfäriska nanopartiklar med snäv storleksfördelning som läkemedelsbärare, partiklar, komposition samt kit
|
JP4129544B2
(ja)
*
|
1993-03-29 |
2008-08-06 |
ファイザー・インク |
サポニンアジュバント使用の多成分系クロストリジウム・ワクチン
|
NL9301690A
(nl)
*
|
1993-08-12 |
1995-04-18 |
Seed Capital Investments |
Verbindingen met adjuvans-activiteit.
|
WO1995009179A1
(en)
*
|
1993-09-30 |
1995-04-06 |
Seed Capital Investments (Sci) B.V. |
Compounds with adjuvant activity
|
AUPM500494A0
(en)
*
|
1994-04-12 |
1994-05-05 |
Minister For Agriculture & Rural Affairs For The State Of New South Wales, The |
Composition for use in increasing mucosal immunity
|
US20030026782A1
(en)
*
|
1995-02-07 |
2003-02-06 |
Arthur M. Krieg |
Immunomodulatory oligonucleotides
|
US6207646B1
(en)
|
1994-07-15 |
2001-03-27 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
AUPM873294A0
(en)
|
1994-10-12 |
1994-11-03 |
Csl Limited |
Saponin preparations and use thereof in iscoms
|
AU686891B2
(en)
*
|
1994-10-12 |
1998-02-12 |
Iscotec A.B. |
Saponin preparations and use thereof in iscoms
|
UA56132C2
(uk)
*
|
1995-04-25 |
2003-05-15 |
Смітклайн Бічем Байолоджікалс С.А. |
Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
|
US20010053365A1
(en)
*
|
1995-04-25 |
2001-12-20 |
Smithkline Beecham Biologicals S.A. |
Vaccines
|
US6290970B1
(en)
|
1995-10-11 |
2001-09-18 |
Aventis Pasteur Limited |
Transferrin receptor protein of Moraxella
|
US6489346B1
(en)
|
1996-01-04 |
2002-12-03 |
The Curators Of The University Of Missouri |
Substituted benzimidazole dosage forms and method of using same
|
US6645988B2
(en)
|
1996-01-04 |
2003-11-11 |
Curators Of The University Of Missouri |
Substituted benzimidazole dosage forms and method of using same
|
US6699885B2
(en)
|
1996-01-04 |
2004-03-02 |
The Curators Of The University Of Missouri |
Substituted benzimidazole dosage forms and methods of using same
|
US5840737A
(en)
|
1996-01-04 |
1998-11-24 |
The Curators Of The University Of Missouri |
Omeprazole solution and method for using same
|
CN1165628A
(zh)
*
|
1996-02-14 |
1997-11-26 |
浙江农业大学 |
茶油饼中提取三萜类皂素作为添加剂的应用
|
US6406705B1
(en)
|
1997-03-10 |
2002-06-18 |
University Of Iowa Research Foundation |
Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
|
DK0996451T3
(da)
*
|
1997-05-20 |
2005-05-23 |
Galenica Pharmaceuticals Inc |
Triterpensaponinanaloger med adjuvans- og immunstimulatorisk aktivitet
|
US6080725A
(en)
*
|
1997-05-20 |
2000-06-27 |
Galenica Pharmaceuticals, Inc. |
Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
|
AUPO732997A0
(en)
*
|
1997-06-12 |
1997-07-03 |
Csl Limited |
Ganglioside immunostimulating complexes and uses thereof
|
GB9718901D0
(en)
*
|
1997-09-05 |
1997-11-12 |
Smithkline Beecham Biolog |
Vaccine
|
US20030022854A1
(en)
|
1998-06-25 |
2003-01-30 |
Dow Steven W. |
Vaccines using nucleic acid-lipid complexes
|
FR2781055B1
(fr)
*
|
1998-07-09 |
2000-10-13 |
Immunotech Sa |
Reactif et methode pour la permeabilisation et l'identification des erythrocytes
|
GB9817052D0
(en)
|
1998-08-05 |
1998-09-30 |
Smithkline Beecham Biolog |
Vaccine
|
US6262029B1
(en)
|
1998-08-14 |
2001-07-17 |
Galenica Pharmaceuticals, Inc. |
Chemically modified saponins and the use thereof as adjuvants
|
AU783344B2
(en)
|
1999-02-17 |
2005-10-20 |
Csl Limited |
Immunogenic complexes and methods relating thereto
|
US6649170B1
(en)
*
|
1999-05-12 |
2003-11-18 |
Statens Serum Institut |
Adjuvant combinations for immunization composition and vaccines
|
US6432411B1
(en)
*
|
1999-07-13 |
2002-08-13 |
Hawaii Biotechnology Group |
Recombinant envelope vaccine against flavivirus infection
|
ES2293923T3
(es)
*
|
1999-09-24 |
2008-04-01 |
Glaxosmithkline Biologicals S.A. |
Vacuna intranasal contra el virus influenza.
|
CA2391843C
(en)
*
|
1999-11-19 |
2011-10-18 |
Csl Limited |
Hcv vaccine compositions
|
US8163289B2
(en)
*
|
2001-03-09 |
2012-04-24 |
Iterative Therapeutics, Inc. |
Methods and compositions involving polymeric immunoglobulin fusion proteins
|
WO2002072608A2
(en)
|
2001-03-09 |
2002-09-19 |
University Of Chicago |
POLYMERIC IMMUNOGLOBULIN FUSION PROTEINS THAT TARGET LOW-AFFINITY FCηRECEPTORS
|
US7713942B2
(en)
*
|
2001-04-04 |
2010-05-11 |
Nordic Vaccine Technology A/S |
Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides
|
EP2011517A1
(en)
|
2001-04-04 |
2009-01-07 |
Nordic Vaccine Technology A/S |
Polynucleotide binding complexes comprising sterols and saponin
|
US6861410B1
(en)
|
2002-03-21 |
2005-03-01 |
Chiron Corporation |
Immunological adjuvant compositions
|
SE0202110D0
(sv)
|
2002-07-05 |
2002-07-05 |
Isconova Ab |
Iscom preparation and use thereof
|
US20050287170A1
(en)
*
|
2002-12-11 |
2005-12-29 |
Hawaii Biotech, Inc. |
Subunit vaccine against West Nile viral infection
|
AU2003300831A1
(en)
*
|
2002-12-11 |
2004-06-30 |
Hawaii Biotech, Inc. |
Recombinant vaccine against flavivirus infection
|
US7381422B2
(en)
*
|
2002-12-23 |
2008-06-03 |
Vical Incorporated |
Method for producing sterile polynucleotide based medicaments
|
AU2003293195A1
(en)
*
|
2002-12-23 |
2004-07-29 |
Vical Incorporated |
Method for freeze-drying nucleic acid/block copolymer/cationic surfactant complexes
|
ES2303046T3
(es)
*
|
2003-01-29 |
2008-08-01 |
Pfizer Products Inc. |
Vacunas caninas contra bordetella bronchiseptica.
|
SE0300795D0
(sv)
|
2003-03-24 |
2003-03-24 |
Isconova Ab |
Composition comprising iscom particles and live micro-organisms
|
SE0301998D0
(sv)
*
|
2003-07-07 |
2003-07-07 |
Isconova Ab |
Quil A fraction with low toxicity and use thereof
|
US8993599B2
(en)
|
2003-07-18 |
2015-03-31 |
Santarus, Inc. |
Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
|
WO2005033278A2
(en)
*
|
2003-09-30 |
2005-04-14 |
Ludwig Institute For Cancer Research |
In vivo efficacy of ny-eso-1 plus iscom
|
KR20110132416A
(ko)
*
|
2004-04-05 |
2011-12-07 |
화이자 프로덕츠 인코포레이티드 |
미세유체화된 수중유 유화액 및 백신 조성물
|
US8906940B2
(en)
|
2004-05-25 |
2014-12-09 |
Santarus, Inc. |
Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
|
US8815916B2
(en)
|
2004-05-25 |
2014-08-26 |
Santarus, Inc. |
Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
|
WO2006060723A2
(en)
*
|
2004-12-03 |
2006-06-08 |
Vical Incorporated |
Methods for producing block copolymer/amphiphilic particles
|
CN101107009B
(zh)
|
2005-01-20 |
2014-08-06 |
伊斯克诺瓦公司 |
包含纤连蛋白结合蛋白或纤连蛋白结合肽的疫苗组合物
|
EP1764369A1
(de)
|
2005-09-16 |
2007-03-21 |
Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH |
Vakzine enthaltend trunkiertes HBV core protein plus Saponin-basierendes Adjuvants
|
ES2325243B1
(es)
|
2008-02-27 |
2011-05-04 |
Universidad De Granada |
Antigeno recombinante.
|
CR20170001A
(es)
|
2008-04-28 |
2017-08-10 |
Genentech Inc |
Anticuerpos anti factor d humanizados
|
HUE028921T2
(en)
*
|
2008-06-27 |
2017-01-30 |
Zoetis Services Llc |
New adjuvant preparations
|
KR101644221B1
(ko)
|
2008-12-09 |
2016-07-29 |
화이자 백신스 엘엘씨 |
IgE CH3 펩티드 백신
|
WO2010125480A1
(en)
|
2009-04-30 |
2010-11-04 |
Coley Pharmaceutical Group, Inc. |
Pneumococcal vaccine and uses thereof
|
RU2518291C2
(ru)
|
2009-07-30 |
2014-06-10 |
Пфайзер Вэксинс ЭлЭлСи |
Антигенные tau-пептиды и их применения
|
MY163512A
(en)
|
2009-09-03 |
2017-09-15 |
Pfizer Vaccines Llc |
Pcsk9 vaccine
|
BR112012009212A2
(pt)
|
2009-10-22 |
2017-06-20 |
Univ Leipzig |
'aplasia de medula óssea com doença hemorrágica em bezerros causada por um novo agente patogênico"
|
RU2581020C2
(ru)
|
2009-12-22 |
2016-04-10 |
Селлдекс Терапьютикс, Инк. |
Композиции вакцин
|
WO2011154878A1
(en)
|
2010-06-07 |
2011-12-15 |
Pfizer Vaccines Llc |
Ige ch3 peptide vaccine
|
CA2798837A1
(en)
|
2010-06-07 |
2011-12-15 |
Pfizer Inc. |
Her-2 peptides and vaccines
|
CA2805741C
(en)
|
2010-07-23 |
2019-08-13 |
Karin Bengtsson Loevgren |
Composition including an iscom matrix and ectodomains
|
CA2808556A1
(en)
|
2010-09-20 |
2012-03-29 |
Crucell Holland B.V. |
Therapeutic vaccination against active tuberculosis
|
US20140004142A1
(en)
|
2011-03-02 |
2014-01-02 |
Pfizer Inc. |
Pcsk9 vaccine
|
CN110680913A
(zh)
|
2011-05-13 |
2020-01-14 |
硕腾有限公司 |
亨德拉和尼帕病毒g糖蛋白免疫原性组合物
|
US9505847B2
(en)
|
2011-08-22 |
2016-11-29 |
Cnj Holdings Inc |
Clostridium difficile antibodies
|
EP2750683B2
(en)
*
|
2011-10-03 |
2021-01-06 |
Croda International PLC |
Nanoparticles, process for preparation and use thereof as carrier for amphipatic of hydrophobic molecules in fields of medicine including cancer treatment and food related compounds
|
SG11201402633UA
(en)
|
2011-11-28 |
2014-09-26 |
Crucell Holland Bv |
Influenza virus vaccines and uses thereof
|
US8932607B2
(en)
|
2012-03-12 |
2015-01-13 |
Crucell Holland B.V. |
Batches of recombinant adenovirus with altered terminal ends
|
SG11201405228VA
(en)
|
2012-03-12 |
2014-11-27 |
Crucell Holland Bv |
Batches of recombinant adenovirus with altered terminal ends
|
EP4218808A3
(en)
*
|
2012-03-12 |
2023-08-09 |
Advanced BioAdjuvants, LLC |
Adjuvant and vaccine compositions
|
US9125870B2
(en)
|
2012-03-22 |
2015-09-08 |
Crucell Holland B.V. |
Vaccine against RSV
|
EP2827895B1
(en)
|
2012-03-22 |
2017-08-09 |
Janssen Vaccines & Prevention B.V. |
Vaccine against rsv
|
EP2659906A1
(en)
|
2012-05-01 |
2013-11-06 |
Affiris AG |
Compositions
|
EP2659907A1
(en)
|
2012-05-01 |
2013-11-06 |
Affiris AG |
Compositions
|
EP2659908A1
(en)
|
2012-05-01 |
2013-11-06 |
Affiris AG |
Compositions
|
SG11201506858SA
(en)
|
2013-03-08 |
2015-09-29 |
Crucell Holland Bv |
Acellular pertussis vaccine
|
WO2014163558A1
(en)
*
|
2013-04-01 |
2014-10-09 |
Moreinx Ab |
Nanoparticles, composed of sterol and saponin from quillaja saponaria molina process for preparation and use thereof as carrier for amphipatic of hydrphobic molecules in fields of medicine including cancer treatment and food related compounds
|
AP2015008815A0
(en)
|
2013-04-25 |
2015-10-31 |
Crucell Holland Bv |
Stabilized soluble prefusion rsv f polypeptides
|
MX369317B
(es)
|
2013-05-30 |
2019-11-05 |
Janssen Vaccines & Prevention Bv |
Vacunas contra el virus de la influenza y sus usos.
|
MY171210A
(en)
|
2013-06-17 |
2019-10-02 |
Janssen Vaccines & Prevention Bv |
Stabilized soluble pre-fusion rsv f polypeptides
|
EP3017040B1
(en)
|
2013-07-02 |
2018-06-06 |
Janssen Vaccines & Prevention B.V. |
Method for preparing virosomes
|
WO2015000831A1
(en)
|
2013-07-02 |
2015-01-08 |
Crucell Holland B.V. |
Method for preparing virosomes
|
MX2016001854A
(es)
|
2013-08-12 |
2016-09-06 |
Genentech Inc |
Composiciones y metodo para tratar condiciones asociadas con el complemento.
|
AU2014391422A1
(en)
|
2013-09-17 |
2015-12-17 |
Obi Pharma, Inc. |
Compositions of a carbohydrate vaccine for inducing immune responses and uses thereof in cancer treatment
|
EP3046580A2
(en)
|
2013-09-19 |
2016-07-27 |
Zoetis Services LLC |
Oil-based adjuvants
|
CN105828836A
(zh)
|
2013-12-16 |
2016-08-03 |
硕腾服务有限责任公司 |
亨德拉病毒和尼帕病毒g糖蛋白免疫原性组合物
|
IL296681B2
(en)
|
2014-01-21 |
2024-09-01 |
Pfizer |
Immunogenic preparations including conjugated capsular saccharide antigens and their uses
|
US11160855B2
(en)
|
2014-01-21 |
2021-11-02 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2015123291A1
(en)
|
2014-02-11 |
2015-08-20 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Pcsk9 vaccine and methods of using the same
|
WO2015127140A2
(en)
|
2014-02-19 |
2015-08-27 |
Jody Berry |
Marburg monoclonal antibodies
|
BR112016020009A2
(pt)
|
2014-04-10 |
2017-10-17 |
Obi Pharma Inc |
anticorpo, composição farmacêutica, método para inibir a proliferação de células cancerígenas, hibridoma
|
CA2944712A1
(en)
|
2014-05-01 |
2015-11-05 |
Genentech, Inc. |
Anti-factor d antibody variants and uses thereof
|
CN106661091B
(zh)
|
2014-07-10 |
2020-10-30 |
扬森疫苗与预防公司 |
流行性感冒病毒疫苗及其用途
|
EP3613764A1
(en)
|
2014-10-15 |
2020-02-26 |
Xenothera |
Composition with reduced immunogenicity
|
MY181175A
(en)
|
2014-11-04 |
2020-12-21 |
Janssen Vaccines & Prevention Bv |
Therapeutic hpv16 vaccines
|
CN107427568B
(zh)
|
2015-01-15 |
2021-12-14 |
辉瑞公司 |
用于肺炎球菌疫苗中的免疫原性组合物
|
US10478487B2
(en)
|
2015-01-16 |
2019-11-19 |
Zoetis Services Llc |
Foot-and-mouth disease vaccine
|
SI3283634T1
(sl)
|
2015-04-14 |
2019-08-30 |
Janssen Vaccines & Prevention B.V. |
Rekombinantni adenovirus, ki izraža dva transgena z dvosmernim promotorjem
|
AU2016271857B2
(en)
|
2015-06-03 |
2020-05-28 |
Affiris Ag |
IL-23-P19 vaccines
|
JP7189014B2
(ja)
|
2015-07-07 |
2022-12-13 |
ヤンセン ファッシンズ アンド プリベンション ベーフェー |
Rsvに対するワクチン
|
CN107849119A
(zh)
|
2015-07-07 |
2018-03-27 |
阿费里斯股份公司 |
用于治疗和预防IgE介导的疾病的疫苗
|
EP3319634B1
(en)
|
2015-07-07 |
2019-08-21 |
Janssen Vaccines & Prevention B.V. |
Stabilized soluble pre-fusion rsv f polypeptides
|
PE20240927A1
(es)
|
2015-07-21 |
2024-04-30 |
Pfizer |
Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados, kits que las comprenden y sus usos
|
EA037295B1
(ru)
|
2015-08-20 |
2021-03-05 |
Янссен Вэксинс Энд Превеншн Б.В. |
Терапевтические вакцины против hpv18
|
EP3344288A1
(en)
|
2015-09-02 |
2018-07-11 |
Janssen Vaccines & Prevention B.V. |
Stabilized viral class i fusion proteins
|
CN114617959A
(zh)
|
2015-09-03 |
2022-06-14 |
诺瓦瓦克斯股份有限公司 |
具有改进的稳定性和免疫原性的疫苗组合物
|
AR105910A1
(es)
|
2015-09-04 |
2017-11-22 |
Obi Pharma Inc |
Matrices de glicano y método de uso
|
SI3307322T1
(sl)
|
2015-09-04 |
2021-08-31 |
Primatope Therapeutics Inc. |
Humanizirana protitelesa proti CD40 in njihove uporabe
|
CN108472382A
(zh)
|
2015-10-30 |
2018-08-31 |
豪夫迈·罗氏有限公司 |
抗-因子d抗体变体缀合物及其用途
|
WO2017075173A2
(en)
|
2015-10-30 |
2017-05-04 |
Genentech, Inc. |
Anti-factor d antibodies and conjugates
|
WO2017085586A1
(en)
|
2015-11-20 |
2017-05-26 |
Pfizer Inc. |
Immunogenic compositions for use in pneumococcal vaccines
|
AU2016379097C1
(en)
|
2015-12-23 |
2021-04-08 |
Pfizer Inc. |
RSV F protein mutants
|
KR20180121786A
(ko)
|
2016-03-29 |
2018-11-08 |
오비아이 파머 인코퍼레이티드 |
항체, 제약 조성물 및 방법
|
US10980894B2
(en)
|
2016-03-29 |
2021-04-20 |
Obi Pharma, Inc. |
Antibodies, pharmaceutical compositions and methods
|
JP7233928B2
(ja)
|
2016-04-05 |
2023-03-07 |
ヤンセン ファッシンズ アンド プリベンション ベーフェー |
Rsvに対するワクチン
|
DK3439672T3
(da)
|
2016-04-05 |
2021-02-15 |
Janssen Vaccines & Prevention Bv |
Stabiliserede opløselige præfusions-rsv-f-proteiner
|
TWI697333B
(zh)
|
2016-04-22 |
2020-07-01 |
台灣浩鼎生技股份有限公司 |
經由Globo系列抗原之免疫活化或免疫調節之癌症免疫療法
|
CN109922829A
(zh)
|
2016-05-02 |
2019-06-21 |
扬森疫苗与预防公司 |
治疗性hpv疫苗组合
|
ES2836598T3
(es)
|
2016-05-30 |
2021-06-25 |
Janssen Vaccines & Prevention Bv |
Proteínas F de RSV prefusión estabilizadas
|
WO2017207477A1
(en)
|
2016-05-30 |
2017-12-07 |
Janssen Vaccines & Prevention B.V. |
Stabilized pre-fusion rsv f proteins
|
CN109312362B
(zh)
|
2016-06-20 |
2022-06-28 |
扬森疫苗与预防公司 |
有效和平衡的双向启动子
|
JP7229151B2
(ja)
|
2016-07-14 |
2023-02-27 |
ヤンセン ファッシンズ アンド プリベンション ベーフェー |
Hpvワクチン
|
KR20190067765A
(ko)
|
2016-07-27 |
2019-06-17 |
오비아이 파머 인코퍼레이티드 |
면역원성/치료 글리칸 조성물 및 그의 용도
|
KR102528998B1
(ko)
|
2016-07-29 |
2023-05-03 |
오비아이 파머 인코퍼레이티드 |
인간 항체, 제약 조성물 및 방법
|
WO2018094414A1
(en)
|
2016-11-21 |
2018-05-24 |
Obi Pharma, Inc. |
Conjugated biological molecules, pharmaceutical compositions and methods
|
PL3570879T3
(pl)
|
2017-01-20 |
2022-06-20 |
Pfizer Inc. |
Kompozycje immunogenne do zastosowania w szczepionkach przeciw pneumokokom
|
AU2018217935B2
(en)
|
2017-02-09 |
2020-04-30 |
Janssen Vaccines & Prevention B.V. |
Potent and short promoter for expression of heterologous genes
|
JP2020519663A
(ja)
|
2017-05-17 |
2020-07-02 |
ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. |
Rsv感染に対する防御免疫を誘導するための方法及び組成物
|
US12083228B2
(en)
|
2017-07-24 |
2024-09-10 |
Novavax, Inc. |
Methods and compositions for treating respiratory disease
|
SG11202001458SA
(en)
|
2017-09-15 |
2020-03-30 |
Janssen Vaccines & Prevention Bv |
Method for the safe induction of immunity against rsv
|
JP7317047B2
(ja)
|
2018-01-23 |
2023-07-28 |
ヤンセン ファッシンズ アンド プリベンション ベーフェー |
インフルエンザウイルスワクチン及びその使用
|
US11633471B2
(en)
|
2018-03-06 |
2023-04-25 |
Unm Rainforest Innovations |
Compositions and methods for reducing serum triglycerides
|
BR112020019108A2
(pt)
|
2018-03-19 |
2020-12-29 |
Novavax, Inc. |
Vacinas polivalentes de nanopartículas de influenza
|
GB201807303D0
(en)
|
2018-05-03 |
2018-06-20 |
London School Of Hygeine & Tropical Medicine |
Glyconjugate vaccines
|
SG11202010469QA
(en)
|
2018-05-23 |
2020-11-27 |
Adc Therapeutics Sa |
Molecular adjuvant
|
US11203645B2
(en)
|
2018-06-27 |
2021-12-21 |
Obi Pharma, Inc. |
Glycosynthase variants for glycoprotein engineering and methods of use
|
US11260119B2
(en)
|
2018-08-24 |
2022-03-01 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
WO2020099383A1
(en)
|
2018-11-13 |
2020-05-22 |
Janssen Vaccines & Prevention B.V. |
Stabilized pre-fusion rsv f proteins
|
CA3120922A1
(en)
|
2018-12-12 |
2020-06-18 |
Pfizer Inc. |
Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
|
CA3136278A1
(en)
|
2019-04-10 |
2020-10-15 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
|
CA3137448A1
(en)
|
2019-04-25 |
2020-10-29 |
Janssen Vaccines & Prevention B.V. |
Recombinant influenza antigens
|
CN113950333A
(zh)
|
2019-05-15 |
2022-01-18 |
扬森疫苗与预防公司 |
使用基于腺病毒的疫苗预防性治疗呼吸道合胞病毒感染
|
AU2020275455A1
(en)
|
2019-05-15 |
2021-12-09 |
Janssen Vaccines & Prevention B.V. |
Co-administration of seasonal influenza vaccine and an adenovirus based respiratory syncytial virus vaccine
|
KR20220057578A
(ko)
|
2019-09-05 |
2022-05-09 |
얀센 백신스 앤드 프리벤션 비.브이. |
인플루엔자 바이러스 백신 및 이의 용도
|
WO2021084429A1
(en)
|
2019-11-01 |
2021-05-06 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
US10953089B1
(en)
|
2020-01-27 |
2021-03-23 |
Novavax, Inc. |
Coronavirus vaccine formulations
|
CN116096732A
(zh)
|
2020-01-31 |
2023-05-09 |
贝斯以色列护理医疗中心有限公司 |
用于预防和治疗冠状病毒感染的组合物和方法-sars-cov-2疫苗
|
WO2021165928A2
(en)
|
2020-02-23 |
2021-08-26 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
KR20230009466A
(ko)
|
2020-05-11 |
2023-01-17 |
얀센 파마슈티칼즈, 인코포레이티드 |
SARS-CoV-2 백신
|
EP4149537A1
(en)
|
2020-05-11 |
2023-03-22 |
Janssen Pharmaceuticals, Inc. |
Rna replicon encoding a stabilized corona virus spike protein
|
MX2022014162A
(es)
|
2020-05-11 |
2023-02-23 |
Janssen Pharmaceuticals Inc |
Proteínas de fusión de la proteína de la espícula del coronavirus estabilizadas.
|
IL299515A
(en)
|
2020-06-29 |
2023-02-01 |
Janssen Vaccines & Prevention Bv |
Immune combination against respiratory syncytial virus infection
|
IL299459A
(en)
|
2020-07-06 |
2023-02-01 |
Janssen Pharmaceuticals Inc |
Proteins fused to stabilized coronavirus spike proteins
|
JP2022060169A
(ja)
|
2020-10-02 |
2022-04-14 |
ファイザー・インク |
Rsv fタンパク質生産のための細胞培養工程
|
AU2021368151B2
(en)
|
2020-10-27 |
2024-09-05 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
US20240000912A1
(en)
|
2020-11-04 |
2024-01-04 |
Pfizer Inc. |
Immunogenic compositions for use in pneumococcal vaccines
|
CA3203043A1
(en)
|
2020-12-23 |
2022-06-30 |
Odile DUVAUX |
Composition of pig polyclonal antibody for its use to treat and/or prevent antibody-dependent macrophage pro-inflammatory cytokine release in a passive anti-infectious immunotherap
|
US20220202923A1
(en)
|
2020-12-23 |
2022-06-30 |
Pfizer Inc. |
E. coli fimh mutants and uses thereof
|
WO2022147373A1
(en)
|
2020-12-31 |
2022-07-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins
|
US20240228548A9
(en)
|
2021-02-19 |
2024-07-11 |
Janssen Vaccines & Prevention B.V. |
Stabilized pre-fusion rsv fb antigens
|
GB202102396D0
(en)
|
2021-02-19 |
2021-04-07 |
Adc Therapeutics Sa |
Molecular adjuvant
|
WO2022175479A1
(en)
|
2021-02-19 |
2022-08-25 |
Janssen Vaccines & Prevention B.V. |
Vaccine combinations against respiratory syncytial virus strain a and b infections
|
AU2022249741A1
(en)
|
2021-04-01 |
2023-09-21 |
Msd International Business Gmbh |
Stabilized pre-fusion piv3 f proteins
|
WO2023020939A1
(en)
|
2021-08-17 |
2023-02-23 |
Janssen Pharmaceuticals, Inc. |
Sars-cov-2 vaccines
|
WO2023047349A1
(en)
|
2021-09-24 |
2023-03-30 |
Janssen Pharmaceuticals, Inc. |
Stabilized coronavirus spike protein fusion proteins
|
WO2023047348A1
(en)
|
2021-09-24 |
2023-03-30 |
Janssen Pharmaceuticals, Inc. |
Stabilized corona virus spike protein fusion proteins
|
WO2023111725A1
(en)
|
2021-12-14 |
2023-06-22 |
Janssen Pharmaceuticals, Inc. |
Sars-cov-2 vaccines
|
WO2023110618A1
(en)
|
2021-12-16 |
2023-06-22 |
Janssen Vaccines & Prevention B.V. |
Stabilized pre-fusion hmpv fusion proteins
|
WO2023196634A2
(en)
|
2022-04-08 |
2023-10-12 |
Flagship Pioneering Innovations Vii, Llc |
Vaccines and related methods
|
WO2023217988A1
(en)
|
2022-05-12 |
2023-11-16 |
Janssen Vaccines & Prevention B.V. |
Stabilized pre-fusion hmpv fusion proteins
|
GB202209588D0
(en)
|
2022-06-29 |
2022-08-10 |
Plant Bioscience Ltd |
Methods and compositions
|
WO2024017682A1
(en)
|
2022-07-18 |
2024-01-25 |
Janssen Vaccines & Prevention B.V. |
Rsv immunogens
|
WO2024030856A2
(en)
|
2022-08-01 |
2024-02-08 |
Flagship Pioneering Innovations Vii, Llc |
Immunomodulatory proteins and related methods
|
WO2024061757A1
(en)
|
2022-09-23 |
2024-03-28 |
Janssen Vaccines & Prevention B.V. |
Pre-fusion human piv1 f proteins
|
WO2024061753A1
(en)
|
2022-09-23 |
2024-03-28 |
Janssen Vaccines & Prevention B.V. |
Stabilized trimeric class i fusion proteins
|
WO2024061759A1
(en)
|
2022-09-23 |
2024-03-28 |
Janssen Vaccines & Prevention B.V. |
Stabilized coronavirus s proteins
|
WO2024074584A1
(en)
|
2022-10-06 |
2024-04-11 |
Janssen Vaccines & Prevention B.V. |
Stabilized pre-fusion piv3 f proteins
|
WO2024104947A2
(en)
|
2022-11-14 |
2024-05-23 |
Janssen Vaccines & Prevention B.V. |
Influenza b virus vaccines and uses thereof
|
SE2200142A1
(en)
*
|
2022-12-13 |
2024-06-14 |
Savacc Ab |
Chrisvacc
|
WO2024151583A2
(en)
|
2023-01-09 |
2024-07-18 |
Flagship Pioneering Innovations Vii, Llc |
Vaccines and related methods
|
WO2024153674A1
(en)
|
2023-01-18 |
2024-07-25 |
Novavax AB |
Methods of quantifying saponins present in particles comprising saponin and lipid
|
US20240252614A1
(en)
|
2023-01-18 |
2024-08-01 |
Pfizer Inc. |
Vaccines against respiratory diseases
|
US20240269263A1
(en)
|
2023-02-06 |
2024-08-15 |
Flagship Pioneering Innovations Vii, Llc |
Immunomodulatory compositions and related methods
|
WO2024175579A1
(en)
|
2023-02-21 |
2024-08-29 |
Janssen Vaccines & Prevention B.V. |
Stabilized trimeric rsv fusion proteins without a heterologous trimerzation domain
|